Business Context and Reporting Period
Company: Onconetix, Inc. (ONCO), a Delaware corporation and emerging growth company.
Reporting Period: February 11, 2026 (Event Date) / February 12, 2026 (Filing Date).
Event: Entry into a Material Definitive Agreement (Share Exchange Agreement) to acquire Realbotix, LLC ("Realbotix"), a technology company focused on AI-powered humanoid robots. The transaction involves Onconetix acquiring all equity interests of Realbotix from Simulacra Corporation (Seller) and Realbotix Corp. (Parent) in exchange for newly issued Onconetix common stock.
Key Financial Metrics and Transaction Terms
Consideration Structure: The transaction is an all-stock exchange. The percentage of fully diluted Onconetix shares owned by the Seller post-closing is contingent on Onconetix's "Net Cash" at closing:
- Net Cash $12.5M - $15.0M: Seller owns 90% of fully diluted shares.
- Net Cash $15.0M - $18.0M: Seller owns 85% of fully diluted shares.
- Net Cash $18.0M - $20.0M: Seller owns 80% of fully diluted shares.
- Net Cash > $20.0M: Seller owns 75% of fully diluted shares.
Net Cash Definition: Cash and cash equivalents held by Onconetix at closing, net of D&O tail insurance, change-of-control payments, indebtedness, certain liabilities, and transaction expenses.
Financial Conditions:
- Net Cash Condition: Closing requires Onconetix to have at least $12.5 million in Net Cash.
- Financing Condition: Onconetix must enter into an equity line of credit agreement for up to $125.0 million.
- Convertible Securities Condition: All Onconetix preferred stock must convert to common stock, and options/warrants must be terminated or amended.
Termination Fees:
- Breach: $500,000 plus transaction expenses (capped at $500,000).
- Superior Proposal/Adverse Recommendation: $500,000 plus expenses, plus an additional $1,500,000 if the superior proposal closes.
- Failure to Meet Net Cash Condition: If Net Cash > $5.0M, Onconetix pays Realbotix transaction expenses (capped at $500,000).
Revenue/Profit/Cash Flow: The filing text does not provide specific revenue, profit, cash flow, or margin figures for Onconetix or Realbotix for any period.
Material Changes and Strategic Shift
Business Transformation: Onconetix is pivoting from its current operations to the robotics and AI sector through the acquisition of Realbotix. Realbotix designs and manufactures AI-powered humanoid robots for customer service, hospitality, and healthcare.
Ownership Structure: Upon closing, Realbotix will become a wholly-owned subsidiary of Onconetix. The Seller (Simulacra/Realbotix Corp) will become the majority shareholder of the combined entity (75% to 90% ownership depending on cash levels).
Board Composition: Post-closing, the Onconetix Board will consist of five directors: one designated by Onconetix and four designated by Realbotix.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Recent Developments (Realbotix):
- Technology: Realbotix integrates third-party LLMs (OpenAI, Meta, Google) and proprietary AI. Recent milestones include multilingual capabilities (15+ languages), autonomous robot-to-robot conversation demonstrations (CES 2026), and partnerships with Tix4, Hollo.AI, and The FUTR Corporation.
- Market: Management cites a projected humanoid robotics market growth from $1.62 billion (2023) to $28 billion (2032).
Risks and Contingencies:
- Transaction Failure: The deal is subject to numerous conditions, including stockholder approval, regulatory consents, and the Net Cash condition. Failure to close could adversely affect Onconetix's stock price and operations.
- Dilution: Existing Onconetix stockholders will experience significant dilution, potentially owning less than 25% of the combined company.
- Integration: Risks include management distraction, operational disruption, and failure to realize anticipated synergies.
- Technology & IP: Risks related to rapid technological change, inability to protect intellectual property, and cybersecurity threats.
- Market Disruption: Potential for major losses due to unexpected market disruptions or illiquidity.
Unusual Items: The transaction structure heavily favors the Seller, who will retain majority control. The deal is contingent on Onconetix securing a $125 million equity line of credit.
Investor Verification Checklist
- Net Cash Position: Verify Onconetix's current cash balance and debt levels to determine if the $12.5 million Net Cash closing condition is achievable.
- Financing Status: Confirm if the $125 million equity line of credit has been secured or is in advanced negotiation.
- Stockholder Approval: Monitor the upcoming special meeting of Onconetix stockholders required to approve the transaction.
- Realbotix Financials: Review the audited financial statements of Realbotix (due by April 31, 2026, per agreement) to assess the target's financial health.
- Dilution Impact: Calculate the exact ownership percentage remaining for current Onconetix shareholders based on the final Net Cash determination.
- Regulatory Approvals: Track the status of any required third-party or regulatory consents.